News-Medical.Net on MSN18h
ViiV Healthcare’s investigational broadly neutralising antibody - N6LS - successfully maintains viral suppression in long-acting treatment of HIVViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced positive findings from the company’s EMBRACE phase IIb study.
Clinical Trials Arena on MSN16h
ViiV to trial twice-yearly HIV antibody dosing after Phase IIb successThe company’s Phase IIb trial found the therapy, N6LS, was able to maintain viral loads below a detectable threshold.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback